Warning Letter Close-Outs – September 2022
Executive Summary
The US FDA released one close-out letter in September, resolving a warning issued to a California device firm in 2017.
You may also be interested in...
Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space
Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.
Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?
Scrip’s Joseph Haas and Jessica Merrill discuss the US FTC’s oversight of the Amgen/Horizon deal and what it might portend for biopharma M&A with Leerink Partners' Dan Lepanto and ZS partner Cody Powers.
IVD DNA Test For Cancer Receives New Regulatory Classification
The approval for Invitae’s cancer risk diagnostic test opens the door for more tests of its kind.